IFNγ-induced stem-like state of cancer cells as a driver of metastatic progression following immunotherapy

Cell Stem Cell. 2023 Jun 1;30(6):818-831.e6. doi: 10.1016/j.stem.2023.05.007.

Abstract

Despite the remarkable success of immune checkpoint blockade (ICB) therapy, most cancer patients still do not respond. We now find that immunotherapy can induce stem-like properties in tumors. Using mouse models of breast cancer, we observe that cancer stem cells (CSCs) show not only enhanced resistance to T cell cytotoxicity, but that interferon gamma (IFNγ) produced by activated T cells directly converts non-CSCs to CSCs. IFNγ enhances several CSC phenotypes, such as resistance to chemo- and radiotherapy and metastasis formation. We identified the branched-chain amino acid aminotransaminase 1 (BCAT1) as a downstream mediator of IFNγ-induced CSC plasticity. Targeting BCAT1 in vivo improved cancer vaccination and ICB therapy by preventing IFNγ-induced metastasis formation. Breast cancer patients treated with ICB exhibited a similar increase in CSC markers expression indicating comparable responses to immune activation in humans. Collectively, we discover an unexpected, pro-tumoral role for IFNγ that may contribute to cancer immunotherapy failure.

Keywords: BCAT1; IFNγ; T cell-induced cancer progression; breast cancer; cancer immunotherapy; cancer plasticity; cancer stem cell; immune checkpoint blockade; immune evasion; metastasis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Breast Neoplasms* / therapy
  • Disease Models, Animal
  • Female
  • Humans
  • Immunotherapy
  • Interferon-gamma*
  • Mice
  • T-Lymphocytes
  • Transaminases

Substances

  • Interferon-gamma
  • BCAT1 protein, human
  • Transaminases